 Connection
Richard Duke to Genetic Therapy
This is a "connection" page, showing publications Richard Duke has written about Genetic Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.441 |
|
|
|
-
Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack J, Duke RC. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther. 2012 Dec; 20(12):2234-43.
Score: 0.365
-
Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999 Feb; 6(2):175-82.
Score: 0.036
-
Walsh P, Dorner A, Duke RC, Su LJ, Glode LM. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst. 1995 Jun 07; 87(11):809-16.
Score: 0.028
-
Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, Dow SW, Bellgrau D, Cutter GR, Helfand SC, Modiano JF. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 2003 Sep; 10(9):726-36.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|